NasdaqGS:ERASBiotechs
Erasca (ERAS) Faces FDA Trial Pause and New Patent Win Is Its RAS Strategy Balanced?
In recent days, the FDA placed a partial clinical hold on Erasca’s Phase 1 BOREALIS-1 trial of its pan-KRAS inhibitor ERAS-4001 after adverse events were observed, pausing parts of a key early-stage cancer study.
This setback comes alongside Erasca securing a long-dated U.S. patent for its pan-RAS molecular glue ERAS-0015, underscoring a contrasting mix of safety uncertainty and potential longer-term competitive protection.
We’ll now examine how the FDA’s partial clinical hold on ERAS-4001...